850142-73-3Relevant articles and documents
N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF
-
Paragraph 0143, (2022/02/28)
This disclosure provides compounds and pharmaceutically acceptable salts thereof of Formula I (Formula I) The variables, e.g. R1-R4, and Z are defined herein. Y is Y is (II). Certain compounds of Formula I are highly potent against resistant tumor cell lines driven by BRAFV600E monomer melanoma cells (A375 or SK-MEL-239), p61-BRAFV600E dimer splice variant melanoma cells (SK-MEL-239-C4) and colorectal (RKO) and lung cancer (A549) cells, and at the same time display a highly desirable pharmacological profile in a mice tumor model.
An efficient coupling of N-tosylhydrazones with 2-halopyridines: Synthesis of 2-α-styrylpyridines endowed with antitumor activity
Lawson, Marie,Hamze, Abdallah,Peyrat, Jean-Fran?ois,Bignon, Jér?me,Dubois, Joelle,Brion, Jean-Daniel,Alami, Mouad
supporting information, p. 3664 - 3673 (2013/06/26)
The synthesis of 2-α-styrylpyridines has been carried out by using the coupling of polyoxygenated N-tosylhydrazones with various 2-halopyridines. We demonstrated that the use of a catalytic amount of PdCl2(MeCN) 2 in combination with a bidentate ferrocene DPPF or a monodentate alkyl phosphine tBu2MeP-HBF4 constitutes an efficient protocol for this coupling, providing 2-α-styrylpyridines 2 in satisfactory to good yields. Among several polyoxygenated derivatives 2 evaluated, compound 2aa was found to exhibit excellent antiproliferative and antimitotic activities comparable to that of the reference compound isoCA-4. The Royal Society of Chemistry 2013.
1-‘2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL!-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS
-
Page/Page column 74-75, (2010/02/11)
This invention provides a compound of the formula (I), wherein R1 and R2 independently represents a hydrogen atom or the like; R3 represents an aryl group having from 6 to 10 ring carbon or the like; said aryl groups havin